coreinv

$BLRX FDA approved Aphexda/Motixafortide, let's see how much it drops! 😅 ir.biolinerx.com/news-releases/…

Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion. $GMAB $MRUS ir.genmab.com/news-releases/…

$NVO $NOVOB #NovoNordisk Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas. $LLY novonordisk.com/content/nncorp…

$NVO

$TEVA #JPM25 slides s24.q4cdn.com/720828402/file…

$AXSM AA trial 3 out of 4 success, decent chance for FDA approval, buying the dip.

$NOVOB CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial $LLY BW loss 22.7% CagriSema vs 11.8% cagrilintide 2.4mg vs 16.1% semaglutide 2.4mg vs 2.3% PBO alone after 68wks so misses its goal of 25+% BW loss PBO adjusted most common AEs with CagriSema = GI w/ vast majority mild to moderate and diminished over time consistent with the GLP-1 receptor agonist class globenewswire.com/news-release/2…

Question is what side effects there are compared to others?

Weight loss dk.

$NOVO down 22% on 22% weight loss seems fitting. Danish stock index C25 hammered. cc @BertrandBio

$TEVA $SAN $SNY Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease (RELIEVE UCCD) #TL1A $MRK $ROG $RHHBY ***primary: MMS for UC & SES-CD in CD (P-values reported 1-sided at a significance level of 0.10)*** UC: 20.5% PBO clin remission in UC OMG!!! PBO strikes again => clin rem 36.2% LD vs 47.8% HD vs 20.45% PBO i.e. PBO-adj +15.7% LD & +27.4% HD @ W14 (p=0.050 and 0.003, respectively). CD: endoscopic response 26.1% LD vs 47.8% HD vs 13% PBO i.e. PBO-adj rates +13.0% LD & +34.8% HD @ W14 (p=0.058 and <0.001, respectively) treatment effect consistent across subgrps. "This is the first and only randomized, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in CD" duvakitug generally well tolerated, no safety signal identified, rates of AEs similar between duvakitug and PBO across both UC and CD (50% vs 50%), all AEs reported across both UC and CD <5% globenewswire.com/news-release/2…

FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer finance.yahoo.com/news/fda-grant… $CANF

Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis finance.yahoo.com/news/projected… $canf

$NOVOB oral amycretin ph1 slides #EASD2024 1/2 $LLY

JUST IN: Over $2.9 trillion has been wiped out from major indices and stocks this morning due to growing fears of a global recession. This is the worst day for stocks since March 16, 2020, during the COVID-19 pandemic fears.

... ox.ac.uk/news/2024-06-0…

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 finance.yahoo.com/news/fite-rece… $CANF

what a shit show 🤦

oral irinotecan (similar to VIP236's 7-Ethyl Camptothecin payload) showed 0% ORR 36% (9/25) had SD (some tumor shrinkage <30%) $VINC ncbi.nlm.nih.gov/pmc/articles/P…

Part 1 of my March email series went out this morning. Thoughts on $CELC, $EWTX, $FULC, $CGEM, and $AVTE. open.substack.com/pub/mattbiotec…

The weight of high-momentum stocks in the US is at its highest point in almost 100 years. Watch out for crowded exits if things turn for the worse.